CD8A and myeloid sarcoma: With these conditions in mind, a longitudinal multi-center MS study could be conducted, in which brain age is examined over time and combined with the CD8+CD57+(PD-1+ILT2+) T-cell activity and another aging biomarker such as the epigenetic clock, derived from DNA methylation patterns (6).